Sanofi (SNY) +2.5%) and its partner KaloBios Pharmaceuticals (KBIO) +5%) say the FDA has granted...


Sanofi (SNY) +2.5%) and its partner KaloBios Pharmaceuticals (KBIO) +5%) say the FDA has granted fast-track designation for the investigation of KB001A, an antibody fragment intended for protection against bacterial pneumonia caused by Pseudomonas aeruginosa in mechanically-ventilated patients. Under the partnership arrangement SNY is responsible for all clinical development, and is currently conducting a Phase I trial of the monoclonal antibody in the U.S. and has started Phase IIb planning.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs